Gabrielle Union Fertility: How the Media Narrative Shifted

What Gabrielle Union Actually Said, and Why It Mattered

Before 2017, mainstream celebrity coverage of Gabrielle Union's reproductive life was almost entirely speculative. Tabloids ran "bump watch" photos, attributed childlessness to career ambition, and occasionally floated unnamed "fertility problems" without clinical context. Union changed the frame herself.

In her memoir We're Going to Need More Wine, published in October 2017, Union disclosed that she had experienced approximately nine miscarriages and failed IVF implantations and that her doctors eventually identified adenomyosis as a likely contributor. She named the condition. She described the physical experience of pregnancy loss in specific, unsentimental language. She did not position herself as a victim or a cautionary tale. That combination, named diagnosis plus first-person clinical detail plus refusal of the tragedy script, was a genuine departure from how celebrity fertility was covered at the time.

The media narrative shifted because the source material shifted. Reporters could no longer speculate when Union had already supplied the pathology report, so to speak.

Adenomyosis: The Condition at the Center of Union's Story

Adenomyosis is not the same as endometriosis, though the two are frequently confused and often coexist. In adenomyosis, the endometrial glands and stroma invade the muscular wall of the uterus (the myometrium) rather than growing outside the uterus as in endometriosis.

How common is it, really?

Prevalence estimates vary because definitive diagnosis historically required hysterectomy and pathology review. With the wider use of transvaginal ultrasound and MRI, population-based estimates now place adenomyosis in roughly 20-35% of women of reproductive age, with higher rates in women who have had prior uterine surgery or who are over 35.

Symptoms that are routinely dismissed

The hallmark symptoms are heavy, painful periods and a bulky, tender uterus. Many women also experience:

• Pelvic pressure between cycles
• Pain with intercourse
• Bloating that worsens in the luteal phase
• Spotting outside of menstruation

These symptoms overlap with fibroids, endometriosis, and PCOS, which is one reason the average time from first symptoms to diagnosis is estimated at 7-12 years across related pelvic conditions. That lag is not a coincidence. It reflects a documented pattern of women's pain being undertreated and underinvestigated.

Adenomyosis and fertility: the clinical picture

A 2020 meta-analysis published in Human Reproduction found that women with adenomyosis had a 28% lower live-birth rate after IVF compared with controls without the condition. Implantation failure and miscarriage rates were also elevated, which maps directly onto what Union described publicly.

The proposed mechanisms include impaired endometrial receptivity, altered uterine contractility during the implantation window, and inflammatory changes in the myometrium that may affect embryo development. Research in this area is active, but the evidence base is still limited by small trials and heterogeneous diagnostic criteria.

The Racial Dimension the Media Initially Missed

Union is a Black woman. Her fertility story is inseparable from the documented disparities in how Black women experience reproductive health care in the United States.

Diagnosis disparities

Black women are more likely to develop uterine fibroids at younger ages and with greater severity than white women, and emerging data suggest similar disparities may exist for adenomyosis, though the research is thin. The 2023 AJOG paper by Eltoukhi et al. Documented that Black women with pelvic pain conditions wait longer for specialist referral than white women presenting with the same symptom burden.

Pain being discounted

Multiple studies, including a 2016 analysis in the Journal of Pain, found that Black patients are undertreated for pain relative to white patients across clinical settings. For a woman with adenomyosis whose primary complaint is pelvic pain and heavy bleeding, this pattern can translate directly into delayed diagnosis and delayed access to fertility-preserving treatment.

Maternal mortality context

Union herself has spoken about the fear Black women carry into medical encounters. That fear is grounded in data: Black women in the U.S. Die from pregnancy-related causes at approximately 2.6 times the rate of white women, according to CDC surveillance data. While maternal mortality is not adenomyosis-specific, the same systemic factors that produce that statistic also shape how Black women are heard, believed, and treated when they report fertility-related symptoms.

When Union named her diagnosis publicly, she gave language to an experience many Black women had been unable to get named in a clinical office.

How the Media Narrative Actually Shifted: A Clinical Journalist's View

The shift in media coverage of Gabrielle Union's fertility happened in three distinct phases, and understanding those phases helps clinicians and health writers recognize the same pattern in other public disclosures.

Phase 1: Speculation without pathology (roughly 2007-2016)

During Union's marriage to Dwyane Wade beginning in 2014, celebrity media ran repeated "baby bump" speculation pieces. The framing was almost universally one of two things: either she didn't want children (coded as selfish), or something was "wrong" with her body (coded as tragedy). Neither frame required a source. Neither frame required a named condition. The woman herself was not the authority on her own reproduction.

This is not unique to Union. The same template was applied to Jennifer Aniston, Oprah Winfrey, and Kim Kardashian before each woman disclosed something that changed the story. Speculation fills the vacuum that medical privacy creates, and women are always the subject, never the expert, in that speculation.

Phase 2: Self-disclosure with clinical specificity (2017-2018)

The memoir changed the coverage type, not just the content. After We're Going to Need More Wine, outlets that had been running speculation pieces began running explainers. "What is adenomyosis?" became a searchable question. Reproductive endocrinologists were quoted. The National Institutes of Health page on the condition received increased traffic. A named diagnosis creates a searchable term, and a searchable term creates educational content.

This is a media mechanism worth naming explicitly: a celebrity disclosing a specific condition is more likely to shift public knowledge than any amount of public health messaging, because the celebrity provides a face, a story, and an emotional hook that a pamphlet cannot.

Phase 3: Normalization and institutional response (2019-present)

Following Kaavia James's birth via gestational carrier in November 2018, coverage shifted again toward surrogacy. ASRM guidelines define gestational surrogacy as an arrangement where a woman (the gestational carrier) carries a pregnancy using an embryo created from the intended parent's egg and sperm or donor material. ASRM has published committee opinions supporting access to third-party reproduction when medical need is established.

For Union, the medical need was established. For many women watching her story, the knowledge that gestational surrogacy was a legal, medically supported option for a woman with recurrent implantation failure was genuinely new information.

Fertility Protocols Relevant to Adenomyosis: What the Science Supports

Women who search "Gabrielle Union fertility protocol" are usually asking what she did and whether it applies to them. The honest answer is that Union has not disclosed the specific stimulation protocols, medications, or embryo transfer details of her IVF cycles. What can be addressed clinically are the approaches that reproductive endocrinologists currently use for women with adenomyosis and recurrent implantation failure.

Suppression before IVF transfer

Several retrospective studies and one small RCT have suggested that prolonged GnRH agonist suppression (typically 2-6 months) before a frozen embryo transfer may improve outcomes in women with adenomyosis by reducing myometrial inflammation. A 2019 study in Fertility and Sterility found that ultra-long GnRH agonist suppression was associated with significantly higher clinical pregnancy rates in adenomyosis patients undergoing FET. The evidence is not yet practice-changing at the guideline level, but ASRM acknowledges it as an active area of investigation.

Progesterone support and endometrial preparation

Endometrial receptivity is the central concern in adenomyosis-related implantation failure. Progesterone supplementation during the luteal phase and during embryo transfer cycles is standard. The form, timing, and route of progesterone administration remain actively studied, with vaginal, intramuscular, and subcutaneous formulations all in use.

Surgical considerations

Adenomyosis is not treated surgically the way endometriosis lesions can be excised. Adenomyotomy (surgical removal of adenomyotic lesions from the myometrium) is performed at some centers, but the evidence for improved IVF outcomes post-surgery is limited to case series and small retrospective data. Hysterectomy is definitive but obviously eliminates any chance of gestational pregnancy, which is why gestational surrogacy becomes the relevant option for women with severe adenomyosis who have exhausted uterine-sparing approaches.

When gestational surrogacy enters the picture

ACOG Committee Opinion 660 outlines the medical, legal, and ethical framework for gestational surrogacy. For women with recurrent pregnancy loss in the setting of adenomyosis, a uterine anomaly, or multiple failed transfers with chromosomally normal embryos, a reproductive endocrinologist may discuss gestational carrier arrangements. The intended mother's embryos are created through standard IVF, and the carrier undergoes a separate frozen embryo transfer protocol.

This is the pathway Union used, and it is a real, clinically supported pathway that many women simply did not know existed before her disclosure.

Life Stage Considerations: Fertility and Adenomyosis Across Your Reproductive Years

Reproductive years (20s to mid-30s)

Adenomyosis is often dismissed as "just bad periods" in younger women. If you have flooding, clots larger than a quarter, or pain that prevents normal activity, asking your gynecologist specifically about adenomyosis and requesting a transvaginal ultrasound or pelvic MRI is appropriate. Early diagnosis may preserve more treatment options.

Trying to conceive (any age, but especially over 35)

If you have been trying to conceive for 6-12 months without success and you have any history of painful or heavy periods, adenomyosis should be part of the diagnostic workup, not an afterthought. A 2021 ACOG Practice Bulletin on recurrent pregnancy loss recommends systematic uterine evaluation including sonohysterography or hysteroscopy as part of the standard workup.

Perimenopause (typically 40s)

Adenomyosis frequently worsens in perimenopause as estrogen levels fluctuate. The uterus may enlarge, and bleeding can become heavier and more irregular. This is also when the overlap with perimenopausal bleeding changes makes diagnosis more complex. If you are in your 40s with worsening pelvic symptoms and a history of difficult periods, adenomyosis deserves attention even if you are no longer seeking pregnancy.

Postmenopause

Adenomyosis generally regresses after menopause as estrogen declines. Women who opt for systemic hormone therapy after menopause should be aware that estrogen-containing regimens may cause symptoms to recur or persist. This is an individualized decision made with a clinician who knows your history.

What Gabrielle Union's Story Tells Us About Evidence Gaps

Union's story also inadvertently illustrated how little high-quality evidence exists specifically for adenomyosis in Black women, for recurrent implantation failure in women over 40, and for gestational surrogacy outcomes in intended mothers with chronic pelvic conditions.

Women have been systematically underrepresented in clinical trials for decades, and within that underrepresentation, Black women are underrepresented further. A 2022 analysis in Obstetrics and Gynecology found that Black women represented fewer than 5% of participants in reproductive endocrinology RCTs published over a 20-year period.

That gap matters for clinical care. When a Black woman with adenomyosis asks her reproductive endocrinologist about her prognosis, the data her doctor is using was almost certainly collected primarily from white and Asian women. The confidence intervals around that prognosis are wider than they should be, and women deserve to know that.

This is not a reason for nihilism. It is a reason to advocate louder for inclusion in research, to be skeptical of statistics quoted without demographic breakdown, and to ask your provider what the evidence specifically says about women like you.

A Note on What Union's Story Cannot Tell You

Public disclosures by celebrities are powerful but incomplete. Union has shared what she chose to share. She has not published her stimulation protocols, her FSH and AMH values, her embryo quality data, or the specific diagnostic criteria her physicians used for adenomyosis. What she has shared is the emotional and experiential arc of the journey, and that is genuinely valuable.

But it should not be mistaken for a replicable protocol. "What did Gabrielle Union do?" is a less useful clinical question than "Given my specific uterine anatomy, ovarian reserve, and history of pregnancy loss, what does the current evidence support for someone with my profile?"

The former question leads to Pinterest boards. The latter leads to a reproductive endocrinologist.

As WomanRx reviewer Elena Vasquez, MD, notes: "What Union's disclosure did that a public health campaign rarely achieves is hand a woman a specific clinical term to bring into a doctor's office. When a patient comes in saying 'I think I might have adenomyosis,' the conversation is completely different than when she says 'I just have bad periods.' The word itself is a diagnostic key."

Who Should Take This Conversation to Their Doctor

You should specifically raise adenomyosis with your OB-GYN or reproductive endocrinologist if:

• Your periods have always been extremely painful or heavy, and you have normalized that pain as "just how you are"
• You have been diagnosed with fibroids but still have significant pelvic pain between cycles
• You have experienced one or more pregnancy losses without a clear explanation
• You have had multiple failed IVF cycles with chromosomally normal embryos
• You are over 38 and starting to think about fertility treatment

You should ask about gestational surrogacy specifically if you have been told your uterus is unlikely to support a pregnancy, or if you have had three or more failed transfers after thorough evaluation and treatment.